FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
The FDA approved Bizengri (zenocutuzumab-zbco) for the treatment of NRG1 fusion-positive cholangiocarcinoma, a rare cancer of the bile ducts. This represents the seventh approval granted under the National Priority Voucher Pilot Program.
The manufacturer of Bizengri and biopharmaceutical companies developing therapies for ultra-rare oncology indications. Impacted functions include regulatory affairs and clinical oncology specialists.
The approval highlights a continued regulatory pathway for ultra-rare, aggressive cancers through specialized pilot programs. The use of the National Priority Voucher Pilot Program suggest the FDA is utilizing specific incentive structures to address unmet needs in niche oncological populations. Regulatory teams may interpret this as a signal that NRG1 fusions are a recognized target for bile duct cancer interventions.
Regulatory teams should monitor the utilization of the National Priority Voucher Pilot Program for similar ultra-rare indications. Operations personnel for NRG1 fusion-positive candidates should review clinical data requirements for these specialized approvals.
FDA issued an approval for Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma, an ultra-rare, aggressive cancer that forms in the bile ducts.
Open in openFDA / FDA.gov